Relationship between glycosylated haernoglobin and mean plasma glucose concentration in cystic fibrosis

被引:28
作者
Brennan, Amanda L.
Gy, Khin M.
Wood, David M.
Hodson, Margaret E.
Geddes, Duncan M.
Baker, Emma H.
机构
[1] Univ London, St Georges, London SW17 0RE, England
[2] Royal Brompton Hosp, Dept Cyst Fibrosis, London SW3 6NP, England
关键词
cystic fibrosis; HbA(1c); cystic fibrosis-related diabetes;
D O I
10.1016/j.jcf.2005.09.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: HbA(1c) is recommended for monitoring glycaemic control in people with cystic fibrosis-related diabetes (CFRD). However the relationship between HbA(1c) and mean plasma glucose concentration (MPG) has not been established in CFRD, as in other forms of diabetes mellitus. Methods: 20 people (13 male, 29.7 +/- 8.8 years, 10 CFRD) with cystic fibrosis (CF) underwent HbA(1c) measurement and 48 h continuous glucose monitoring for estimation of MPG. The relationship between HbA(1c) and MPG was established and compared to the reported relationship for type 1 diabetes. Results: HbA(1c) was strongly correlated with MPG (R-2 = 0.888, p<0.0001) in CF. The relationship of MPG to HbA(1c) was described by the equation MPG =(1.47 x HbA(1c))- 1.15, giving a 1.47 mmol L-1 change in MPG per 1% change in HbA(1c). This equation predicts that MPG in people with CF and HbA(1c) <7.0% will be similar to MPG in people with type 1 diabetes who achieve the same HbA(1c) target. Conclusions: These results imply that HbA(1c) < 7.0% will predict good blood glucose control in CF as in type 1 diabetes. However, although HbA(1c) predicts complications in type 1 diabetes, further studies are required to establish the relationship between HbA(1c) and diabetic complications in people with CFRD. (C) 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 25 条
  • [1] *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS97, DOI DOI 10.2337/DIACARE.25.2007.S97
  • [2] *AM DIAB ASS, 2001, DIABETES CARE S1, V24, pS33
  • [3] [Anonymous], 2010, PAT REG ANN REP
  • [4] ATER JL, 1983, PEDIATRICS, V71, P810
  • [5] BRENNAN AL, 2004, J CYST FIBROS, V3, pS81
  • [6] Brennan Amanda L, 2004, J Cyst Fibros, V3, P209, DOI 10.1016/j.jcf.2004.08.001
  • [7] Fogh-Andersen N, 1998, CLIN CHEM, V44, P655
  • [8] HbA1c is not recommended as a screening test for diabetes in cystic fibrosis
    Holl, RW
    Buck, C
    Babka, C
    Wolf, A
    Thon, A
    [J]. DIABETES CARE, 2000, 23 (01) : 126 - 126
  • [9] Potential impact of HbA1c determination on clinical decision making in patients with cystic fibrosis-related diabetes
    Hunkert, F
    Lietz, T
    Stach, B
    Kiess, W
    [J]. DIABETES CARE, 1999, 22 (06) : 1008 - 1009
  • [10] DIABETES-MELLITUS IN DANISH CYSTIC-FIBROSIS PATIENTS - PREVALENCE AND LATE DIABETIC COMPLICATIONS
    LANNG, S
    THORSTEINSSON, B
    LUNDANDERSEN, C
    NERUP, J
    SCHIOTZ, PO
    KOCH, C
    [J]. ACTA PAEDIATRICA, 1994, 83 (01) : 72 - 77